(0.91%) 5 064.20 points
(0.85%) 38 226 points
(1.51%) 15 841 points
(0.33%) $79.21
(0.15%) $2.04
(0.15%) $2 313.10
(0.28%) $26.91
(0.11%) $963.70
(-0.02%) $0.932
(-0.06%) $10.98
(-0.06%) $0.797
(-0.01%) $91.12
5 days till quarter result
(bmo 2024-05-07)
Expected move: +/- 0.00%
Live Chart Being Loaded With Signals
Kyowa Kirin Co., Ltd. manufactures and markets pharmaceuticals that focuses on the therapeutic areas of oncology, nephrology, central nervous system, and immunology worldwide...
Stats | |
---|---|
Šios dienos apimtis | 954 600 |
Vidutinė apimtis | 1.32M |
Rinkos kapitalizacija | 1 434.07B |
EPS | ¥0 ( 2024-02-06 ) |
Kita pelno data | ( ¥28.50 ) 2024-05-07 |
Last Dividend | ¥27.00 ( 2023-06-29 ) |
Next Dividend | ¥0 ( N/A ) |
P/E | 24.75 |
ATR14 | ¥0.780 (0.03%) |
Tūris Koreliacija
Kyowa Kirin Co., Ltd. Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Kyowa Kirin Co., Ltd. Koreliacija - Valiuta/Žaliavos
Kyowa Kirin Co., Ltd. Finansinės ataskaitos
Annual | 2023 |
Pajamos: | ¥442.23B |
Bruto pelnas: | ¥320.62B (72.50 %) |
EPS: | ¥151.03 |
FY | 2023 |
Pajamos: | ¥442.23B |
Bruto pelnas: | ¥320.62B (72.50 %) |
EPS: | ¥151.03 |
FY | 2022 |
Pajamos: | ¥398.37B |
Bruto pelnas: | ¥311.46B (78.18 %) |
EPS: | ¥99.68 |
FY | 2021 |
Pajamos: | ¥352.25B |
Bruto pelnas: | ¥264.40B (75.06 %) |
EPS: | ¥97.20 |
Financial Reports:
No articles found.
Kyowa Kirin Co., Ltd. Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
¥0 (N/A) |
¥27.00 (N/A) |
¥0 (N/A) |
¥27.00 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | ¥2.50 | 2000-03-28 |
Last Dividend | ¥27.00 | 2023-06-29 |
Next Dividend | ¥0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 49 | -- |
Total Paid Out | ¥539.50 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 4.49 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 7.39 | |
Div. Directional Score | 10.00 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Furthermore, its high Dividend Growth Potential Score (DGPS) signals potential dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
9386.T | Ex Dividend Knight | 2023-12-28 | Semi-Annually | 0 | 0.00% | |
8065.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
7337.T | Ex Dividend Junior | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
6586.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
5932.T | Ex Dividend Junior | 2023-11-29 | Annually | 0 | 0.00% | |
4612.T | Ex Dividend Knight | 2023-12-28 | Semi-Annually | 0 | 0.00% | |
3839.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
3091.T | Ex Dividend Knight | 2023-12-28 | Semi-Annually | 0 | 0.00% | |
1961.T | Ex Dividend Junior | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
9972.T | Ex Dividend Junior | 2023-11-29 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.184 | 1.500 | 6.33 | 9.49 | [0 - 0.5] |
returnOnAssetsTTM | 0.0791 | 1.200 | 7.36 | 8.83 | [0 - 0.3] |
returnOnEquityTTM | 0.101 | 1.500 | 9.99 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.358 | -1.000 | 6.42 | -6.42 | [0 - 1] |
currentRatioTTM | 4.59 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 3.93 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 3.03 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.0232 | -1.500 | 9.61 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 535.43 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 214.94 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 153.83 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.0285 | -1.500 | 9.89 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.742 | 1.000 | 0.962 | 0.962 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.230 | 1.000 | 7.40 | 7.40 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 4.84 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.431 | 0.800 | -0.460 | -0.368 | [0.5 - 2] |
Total Score | 12.77 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 17.72 | 1.000 | 8.31 | 0 | [1 - 100] |
returnOnEquityTTM | 0.101 | 2.50 | 9.99 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 153.83 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 2.09 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 214.94 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.358 | 1.500 | 6.42 | -6.42 | [0 - 1] |
pegRatioTTM | 7.67 | 1.500 | 10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.261 | 1.000 | 5.97 | 0 | [0.1 - 0.5] |
Total Score | 7.39 |
Kyowa Kirin Co., Ltd.
Kyowa Kirin Co., Ltd. manufactures and markets pharmaceuticals that focuses on the therapeutic areas of oncology, nephrology, central nervous system, and immunology worldwide. Its products include ABSTRAL, a sublingual formulation of fentanyl used for the management of episodes of breakthrough pain experienced by cancer patients; ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; ESPO, a glycoprotein and human erythropoietin; NESP, an erythropoiesis stimulating agent; and GRAN, a human colony-stimulating factor. The company also develops G-LASTA/Peglasta/Neulasta for chemotherapy-induced febrile neutropenia; LEUNASE for acute lymphoblastic leukemia; LUMICEF, a biological treatment for moderate to severe plaque psoriasis; Moventig, a mu-opioid receptor antagonist for the treatment of opioid induced constipation; Nouriast/ Nourianz, an adenosine receptor antagonist for Parkinson's disease; and ORKEDIA, an oral calcimimetics agent. In addition, it offers PecFent, a nasally administrated spray; POTELIGEO, a humanized monoclonal antibody for CC chemokine receptor 4; REGPARA for the treatment of secondary hyperparathyroidism; Romiplate/Nplate, a genetically recombinant protein for platelet production of thrombopoietin receptors; and SANCUSO for the treatment of nausea and vomiting. Kyowa Kirin Co., Ltd. has an agreement with Amgen Inc. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in June 2019. The company was incorporated in 1949 and is headquartered in Tokyo, Japan. Kyowa Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.